FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306317951> ?p ?o ?g. }

• W4306317951 abstract "Abstract Background A short DAPT duration after coronary stenting has been associated with similar ischemic outcomes and fewer bleeding complications in patients at high bleeding risk (HBR). Whether these effects are preserved irrespective of concomitant oral anticoagulant (OAC) therapy remains unclear. Purpose To evaluate the safety and efficacy of 1-month versus 3-month DAPT among HBR patients with or without indication to OAC therapy who undergo cobalt-chromium everolimus-eluting stent implantation. Methods The XIENCE Short DAPT Program comprises three prospective, international, single-arm studies evaluating 1-month (XIENCE 28 USA and Global) or 3-month (XIENCE 90) DAPT in HBR patients who had undergone successful everolimus-eluting XIENCE stent implantation. OAC therapy at discharge was a study inclusion criterion. Subjects were eligible to discontinue DAPT at 1 or 3 months if free from ischemic events and adherent to DAPT. The primary endpoint was the composite of all-cause death or any myocardial infarction (MI). The major secondary endpoint was Bleeding Academic Research Consortium (BARC) type 2–5 bleeding. In this exploratory analysis, HBR patients on 1-month DAPT were compared with those on 3-month DAPT according to the presence of background OAC therapy. Ischemic and bleeding outcomes were assessed between 1 and 12 months after index PCI using propensity-score (PS) adjustment. Results A total of 3,364 patients, 1,392 on 1-month DAPT and 1,972 on 3-month DAPT, were eligible for the analyses. Patients on OAC therapy (n=1424, 42.3%) were younger, more often male and of white race, and with a lower prevalence of other HBR criteria such as chronic kidney disease and anemia. The incidence of death or MI at 12 months was similar between the two groups (8.0% vs 7.9%) while BARC 2–5 bleeding was higher in OAC patients (12.2% vs 7.2%). After PS adjustment, 1-month DAPT, compared with 3-month DAPT, did not increase the 1-year risk of death or MI in both OAC (adjHR 0.71, 95% CI 0.47–1.08) and non-OAC patients (adjHR 1.24, 95% CI 0.88–1.75; p-interaction = 0.11). The risk of BARC 2–5 bleeding was consistently reduced in both OAC (adjHR 0.71, 95% CI 0.51–1.00) and non-OAC patients (adjHR 0.77, 95% CI 0.53–1.11; p-interaction = 0.69). Conclusions Among HBR patients undergoing everolimus-eluting stent implantation, 1-month DAPT compared with 3-month DAPT was associated with similar ischemic outcomes and reduced bleeding, regardless of concomitant OAC therapy. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Abbott" @default.
• W4306317951 created "2022-10-16" @default.
• W4306317951 creator A5003432010 @default.
• W4306317951 creator A5008714150 @default.
• W4306317951 creator A5032028897 @default.
• W4306317951 creator A5041420387 @default.
• W4306317951 creator A5073733918 @default.
• W4306317951 creator A5079588095 @default.
• W4306317951 date "2022-10-01" @default.
• W4306317951 modified "2023-10-18" @default.
• W4306317951 title "Dual antiplatelet therapy for 1 versus 3 months in high bleeding risk patients with or without oral anticoagulant therapy after coronary stenting" @default.
• W4306317951 doi "https://doi.org/10.1093/eurheartj/ehac544.2722" @default.
• W4306317951 hasPublicationYear "2022" @default.
• W4306317951 type Work @default.
• W4306317951 citedByCount "0" @default.
• W4306317951 crossrefType "journal-article" @default.
• W4306317951 hasAuthorship W4306317951A5003432010 @default.
• W4306317951 hasAuthorship W4306317951A5008714150 @default.
• W4306317951 hasAuthorship W4306317951A5032028897 @default.
• W4306317951 hasAuthorship W4306317951A5041420387 @default.
• W4306317951 hasAuthorship W4306317951A5073733918 @default.
• W4306317951 hasAuthorship W4306317951A5079588095 @default.
• W4306317951 hasBestOaLocation W43063179511 @default.
• W4306317951 hasConcept C126322002 @default.
• W4306317951 hasConcept C141071460 @default.
• W4306317951 hasConcept C164705383 @default.
• W4306317951 hasConcept C168563851 @default.
• W4306317951 hasConcept C203092338 @default.
• W4306317951 hasConcept C2776999253 @default.
• W4306317951 hasConcept C2778583881 @default.
• W4306317951 hasConcept C2779384505 @default.
• W4306317951 hasConcept C2780400711 @default.
• W4306317951 hasConcept C45393284 @default.
• W4306317951 hasConcept C500558357 @default.
• W4306317951 hasConcept C71924100 @default.
• W4306317951 hasConceptScore W4306317951C126322002 @default.
• W4306317951 hasConceptScore W4306317951C141071460 @default.
• W4306317951 hasConceptScore W4306317951C164705383 @default.
• W4306317951 hasConceptScore W4306317951C168563851 @default.
• W4306317951 hasConceptScore W4306317951C203092338 @default.
• W4306317951 hasConceptScore W4306317951C2776999253 @default.
• W4306317951 hasConceptScore W4306317951C2778583881 @default.
• W4306317951 hasConceptScore W4306317951C2779384505 @default.
• W4306317951 hasConceptScore W4306317951C2780400711 @default.
• W4306317951 hasConceptScore W4306317951C45393284 @default.
• W4306317951 hasConceptScore W4306317951C500558357 @default.
• W4306317951 hasConceptScore W4306317951C71924100 @default.
• W4306317951 hasIssue "Supplement_2" @default.
• W4306317951 hasLocation W43063179511 @default.
• W4306317951 hasOpenAccess W4306317951 @default.
• W4306317951 hasPrimaryLocation W43063179511 @default.
• W4306317951 hasRelatedWork W2355614377 @default.
• W4306317951 hasRelatedWork W2375232986 @default.
• W4306317951 hasRelatedWork W2375584960 @default.
• W4306317951 hasRelatedWork W2378890344 @default.
• W4306317951 hasRelatedWork W2380518343 @default.
• W4306317951 hasRelatedWork W2382579536 @default.
• W4306317951 hasRelatedWork W2414025265 @default.
• W4306317951 hasRelatedWork W2595368886 @default.
• W4306317951 hasRelatedWork W2782203991 @default.
• W4306317951 hasRelatedWork W3029448752 @default.
• W4306317951 hasVolume "43" @default.
• W4306317951 isParatext "false" @default.
• W4306317951 isRetracted "false" @default.
• W4306317951 workType "article" @default.